Radiopharm Theranostics Ltd business relationships
Companies named in Radiopharm Theranostics Ltd’s 20-F filed 2026-09-30, and public companies whose annual reports name Radiopharm Theranostics Ltd. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 23 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Radiopharm Theranostics Ltd’s annual report 5
“Under the agreement, we sold to Lantheus Holdings (i) the rights to the” SEC filing
“RAD 203 has been licensed to Lantheus Molecular Imaging ("Lantheus")” SEC filing
“the assignment of the DUNP19 assets to Lantheus Omega, thus terminating the Exclusive License Agreement, dated March 22, 2022, with The” SEC filing
“from a loss of A$65,300 in fiscal 2025 to A$112,396 in fiscal 2026, mainly unwinding of interest in the Lantheus co-collaboration agreement.” SEC filing
“The group has the license agreement with Diaprost AB.” SEC filing
Companies whose annual reports name Radiopharm Theranostics Ltd 1
“...r LNTH-2401 and LNTH-2402 relating to RM2, (B) the development of LNTH-2403 and LNTH-2404, the associated investment in Radiopharm Theranostics Limited ("Radiopharm") and our co-development partnership with Radiopharm relating to the clinical development of our innovative products and product candid...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.